Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.

Smith KJ, Zimmerman RK, Lin CJ, Nowalk MP, Ko FS, McEllistrem MC, Roberts MS.

Vaccine. 2008 Mar 10;26(11):1420-31. doi: 10.1016/j.vaccine.2008.01.007. Epub 2008 Jan 29.

PMID:
18272262
2.

Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions.

Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M.

Vaccine. 2009 Aug 6;27(36):4891-904. doi: 10.1016/j.vaccine.2009.05.061. Epub 2009 Jun 9. Review.

PMID:
19520205
3.

[Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].

De Graeve D, Verhaegen J, Ament A, Baltussen R.

Acta Clin Belg. 2000 Sep-Oct;55(5):257-65. Dutch.

PMID:
11109640
4.

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK.

JAMA. 2012 Feb 22;307(8):804-12. doi: 10.1001/jama.2012.169.

5.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
6.

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.

Bergman A, Hjelmgren J, Ortqvist A, Wisløff T, Kristiansen IS, Högberg LD, Persson KM, Persson U.

Scand J Infect Dis. 2008;40(9):721-9. doi: 10.1080/00365540802014872.

PMID:
18712627
7.

[Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].

Ortqvist A, Jönsson B, Baltussen R, Ament A.

Lakartidningen. 2000 Nov 8;97(45):5120-5. Swedish.

PMID:
11116891
8.

Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.

Smith KJ, Nowalk MP, Raymund M, Zimmerman RK.

Vaccine. 2013 Aug 20;31(37):3950-6. doi: 10.1016/j.vaccine.2013.06.037. Epub 2013 Jun 24.

9.

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.

Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK.

Vaccine. 2010 Nov 10;28(48):7620-5. doi: 10.1016/j.vaccine.2010.09.053. Epub 2010 Sep 29.

10.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

PMID:
25919163
11.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
12.

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

Cho BH, Stoecker C, Link-Gelles R, Moore MR.

Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.

PMID:
24148572
13.

Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.

Castañeda-Orjuela C, Alvis-Guzmán N, Paternina AJ, De la Hoz-Restrepo F.

Vaccine. 2011 Oct 13;29(44):7644-50. doi: 10.1016/j.vaccine.2011.08.006. Epub 2011 Aug 18.

PMID:
21854825
14.

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.

Neto JT, de Araujo GT, Gagliardi A, Pinho A, Durand L, Fonseca M.

Hum Vaccin. 2011 Oct;7(10):1037-47. doi: 10.4161/hv.7.10.15987. Epub 2011 Oct 1.

15.

Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK.

Am J Prev Med. 2013 Apr;44(4):373-81. doi: 10.1016/j.amepre.2012.11.035.

16.

Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.

Tilson L, Usher C, Butler K, Fitzsimons J, O'Hare F, Cotter S, O'Flanagan D, Johnson H, Barry M.

Value Health. 2008 Sep-Oct;11(5):898-903. doi: 10.1111/j.1524-4733.2008.00341.x. Epub 2008 May 16.

17.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.

Blank PR, Szucs TD.

Vaccine. 2012 Jun 13;30(28):4267-75. doi: 10.1016/j.vaccine.2012.04.028. Epub 2012 Apr 20.

PMID:
22521287
18.

Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.

Middleton DB, Lin CJ, Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS, Fox DE.

Infect Control Hosp Epidemiol. 2008 May;29(5):385-94. doi: 10.1086/587155.

PMID:
18521990
19.

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ.

Pharmacoeconomics. 2006;24(2):141-53.

PMID:
16460135
20.

Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.

Lin CJ, Zimmerman RK, Smith KJ.

Am J Manag Care. 2013 Jan 1;19(1):e30-7.

Supplemental Content

Support Center